Human epidermal growth factor receptor 2 (HER2) plays an important role in the pathogenesis of various cancers. HER2 alterations have been suggested to be a therapeutic target in non-small-cell lung cancer (NSCLC), just as in breast and gastric cancers. We previously reported that the pan-HER inhibitor afatinib could be a useful therapeutic agent as HER2-targeted therapy for patients with NSCLC harboring 
marked antitumor activity in patients with non-small cell lung cancer (NSCLC) carrying activating EGFR mutations. 1 Other oncogenic alterations, such as ALK, KRAS, NRAS, BRAF, MET and FGFR, have also been identified in some subsets of NSCLC patients as possible treatment targets. [2] [3] [4] Human epidermal growth factor receptor 2 (HER2) is a member of the HER family, which is composed of 4 receptor tyrosine kinases (RTK). It is frequently overexpressed in various human cancers, and many preclinical studies have demonstrated that overexpression of HER2 or mutations of the HER2 kinase domain play an important role in oncogenic transformation and tumorigenesis. [5] [6] [7] [8] In the case of breast and gastric cancers, targeted therapies in patients with HER2-positive tumors have been clinically proven to be effective. 9, 10 Among NSCLC patients, the reported frequency of HER2 overexpression and HER2 amplification are 11%-32% and 2%-23%, respectively.
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HER2 mutations are identified in approximately 2%-4% of NSCLC and are usually mutually exclusive of other driver mutations. 15, 16 However, it remains to be established whether HER2-targeted therapy is of clinical benefit in patients with HER2-altered NSCLC. Previous clinical trials have failed to show any clinical benefit of trastuzumab monotherapy or any additional effect of trastuzumab over conventional first-line chemotherapy in HER2-positive NSCLC patients. [17] [18] [19] However, subsets of patients with high HER2 expression levels, HER2
gene amplification or HER2 mutations have been demonstrated to show a good response to HER2-targeted treatment. 17, 20, 21 In addition, a recent retrospective study showed that HER2-targeted therapy was beneficial in combination with chemotherapy for patients with HER2-mutant NSCLC. 22 These findings suggest the potential usefulness of HER2-targeted therapy in HER2-altered NSCLC patients.
Afatinib, also known as BIBW2992, is an irreversible pan-HER (EGFR, HER2, HER3 and HER4) inhibitor, and has recently been approved for the treatment of NSCLC patients carrying EGFR mutations in the tumor. We previously reported that afatinib could inhibit cell growth in both HER2-amplified and HER2-mutant NSCLC cells, just as in EGFR-mutant NSCLC cells, through G1 arrest and apoptosis. 23 In clinical settings, afatinib monotherapy was effective in 3 out of 3 assessable patients with an HER2-mutated adenocarcinoma in an exploratory study of 5 patients. 21 In addition, the recent retrospective studies showed the potential benefit of afatinib for patients with HER2-mutant lung cancers. 22, 24 While further prospective studies including randomized trials are required, afatinib could be approved as one of the therapeutic options for HER2-altered NSCLC patients.
However, development of acquired resistance to afatinib, just like the case for other HER inhibitors, has been reported in most EGFRmutant NSCLC patients treated with afatinib, 25, 26 and the situation is considered to be similar for HER2-altered NSCLC patients. Therefore, overcoming acquired resistance to afatinib is a critical clinical issue.
In this study, we experimentally established various afatinib-resistant cell lines from HER2-altered NSCLC cell lines as the parental cell lines, and examined the molecular profiles of these cells to uncover the mechanisms of acquisition of the drug resistance, and investigated the treatment strategies for these cells with acquired resistance to afatinib.
| MATERIALS AND METHODS

| Reagents and cell cultures
Three NSCLC cell lines (Calu3, NCI-H2170 [H2170] and NCI-H1781
[H1781]), purchased from ATCC (Manassas, VA, USA), were used as the patent cell lines for this study. These cell lines were authenticated by ATCC using short-tandem-repeat polymorphism analysis, and used within 6 months of receipt. All the lung cancer cells were cultured in RPMI-1640 media supplemented with 10% FBS, in a humidified incubator with 5% CO 2 were established by the high concentration method (Table 1) .
Acquired resistance was defined as an IC50 value of over a 100-fold higher than that for the parental cell line. Afatinib and docetaxel were purchased from Synkinase (San Diego, CA, USA) and Wako Pure Chemical Industries (Osaka, Japan), respectively. Crizotinib and elacridar were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Details of the phospho-receptor tyrosine kinase array and the cell proliferation assay are included in Document S1.
| DNA and RNA extraction
Genomic DNA were extracted from the cell lines using the DNeasy Blood and Tissue Kit (Qiagen, Venlo, the Netherlands), and total RNA were extracted using the RNeasy Mini Kit (Qiagen). Complementary DNA (cDNA) was synthesized from total RNA using a T A B L E 1 Afatinib-resistant cell lines and the resistance mechanisms
Cell lines
Afatinib exposure HER2 amp/mut
amp, amplification; CSC, cancer stem cell; EMT, epithelial-to-mesenchymal transition; mut, mutation; N/A, not applicable. 
| Direct sequencing
We determined the mutational status of the tyrosine kinase domain of HER2 by direct sequencing; the PCR conditions employed are shown in Table S1B .
| Western blot analysis
The total cell lysate was extracted with lysis buffer, a mixture of RIPA buffer, phosphatase inhibitor cocktails 2 and 3 (Sigma-Aldrich) and Complete Mini (Roche, Basel, Switzerland). Western blot analysis was carried out using the conventional method using the following 
| mRNA expression analysis by quantitative reverse-transcription PCR
The gene expressions of the putative cancer stem cell (CSC) markers ALDH1A1, ABCB1, CD44, Oct-4 and CD133 were analyzed by qRT-PCR using the cDNA, TaqMan Gene Expression Assays, and the ABI StepOnePlus Real-Time PCR Instrument (Thermo Fisher Scientific). The mRNA expression was calculated using the delta-delta-CT method. The glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene was used as the endogenous control. The catalog numbers of the TaqMan assays are shown in Table S1C .
| Cell growth inhibition assay
Cells were cultured with or without afatinib for 72 hours and the sensitivity to the drug was determined by a modified MTS assay using
CellTiter 96 Aqueous One Solution Reagent (Promega, Fitchburg, WI, USA), as previously described. 28 The antiproliferative effect of each drug was expressed in terms of the IC50 value, which refers to the concentration of the drug required to inhibit cell proliferation by 50%.
| Xenograft model
Six-week-old BALB/c-nu/nu female mice were purchased from Charles River Laboratories (Yokohama, Japan). All mice were provided with sterilized food and water, and housed in a barrier facility under 
| Statistical analysis
All data were analyzed using the JMP v 9.0.0 software (SAS Institute, Cary, NC, USA). Differences among groups were compared by t test. P < .05 was considered as denoting statistical significance. All tests were 2-sided.
3 | RESULTS
| Genotypic mechanisms underlying the development of acquired resistance to afatinib
We established 6 afatinib-resistant cell lines from the 3 parental NSCLC cell lines harboring HER2 alterations, including 2 TORIGOE ET AL.
| 1495 HER2-amplified cell lines (Calu3 and H2170) and 1 HER2-mutant cell line (H1781). To investigate the genotypic changes in the cells with acquired resistance to afatinib, we examined the copy number of HER2, EGFR and MET, gain of which is well known as a mechanism underlying the resistance to HER inhibitors. 29 Significant copy number gains of MET were detected in the Calu3-ARS cells ( Figure 1A ).
In addition, the HER2 copy number was almost lost in the H2170-ARS and H2170-ARH cells. Copy number analysis also revealed progressive decrease of the HER2 copy number of H2170-ARS cells with increasing number of passages, eventually leading to the disappearance of the amplified HER2 alleles ( Figure 1B) . To investigate the mechanism underlying the progressive decrease of the copy number of HER2, we performed the FISH assay and found that all of H2170 parental cells harbored amplified HER2 alleles ( Figure 1C) . Figure 2A) ; furthermore, the resistant cells had acquired a spindle-like shape in contrast to the morphology of the corresponding parental Calu3 cells ( Figure 2B ). These findings suggest the occurrence of epithelial-to-mesenchymal transition (EMT) in the Calu3-ARH, which was considered as being the mechanism underlying the resistance to afatinib.
Next, we investigated the expression levels of ALDH1A1, ABCB1, CD44, Oct-4 and CD133, which are putative CSC markers in NSCLC ( Figure 2C and Figure S2A ). ALDH1A1 was found to be overexpressed in the H1781-ARS and H1781-ARH cells as compared to the parental H1781 cells. Western blot analysis also revealed overexpression of ALDH1A1 in the H1781-ARS and H1781-ARH cells (Figure 2A ). These cell lines with acquired resistance of afatinib were non-adhesive and capable of forming sphere-like clusters ( Figure 2B ).
We conducted a sphere formation assay to examine the cellular functional features of CSC-like properties, 28 and found that H1781-ARS and H1781-ARH cells acquired higher ability to form spheres in suspension culture compared with parental H1781 cells ( Figure S2B ).
To examine the CSC-like properties in vivo, we conducted tumor transplantation experiments. 28, 30, 31 We subcutaneously implanted H1781, H1781-ARS and H1781-ARH cells to examine the tumorforming capability in NOD/SCID mice. We found that H1781-ARS and H1781-ARH cells exhibited higher tumorigenicity than parental H1781 cells. The H1781-ARS and H1781-ARH cells established larger tumors with shorter latencies than the parental H1781 cells ( Figure S2C ). These findings suggest that the H1781-ARS and H1781-ARH cells had acquired CSC-like properties, which could be considered as the mechanism underlying the resistance to afatinib.
ABCB1 was overexpressed in the H2170-ARS and H2170-ARH cells,
but not in either the H1781-ARS or H1781-ARH cells ( Figure 2C ).
CD44, Oct-4 and CD133 overexpression was not detected in any of
the resistant cell lines.
| Drug sensitivities of the afatinib-resistant cells showing MET amplification
The sensitivities of the cells to various drugs are shown in Table 2 . 
| Sensitivity of the afatinib-resistant cells to chemotherapeutic agents
The H2170-ARS and H2170-ARH cells, which had lost HER2 amplification, also acquired resistance to docetaxel (Table 2) . To investigate whether their resistance mechanism was associated with overexpression of ATP-binding Cassette sub-family B Member 1 (ABCB1), which is well known to induce resistance to chemotherapy, we inhibitor elacridar ( Figure S3A,B) . We found that elacridar recovered the sensitivity to docetaxel, but not to afatinib in H2170-ARS and H2170-ARH cells. These findings were similar to those in our previous report using docetaxel-resistant NSCLC cells with EGFR-mutations. 32 In contrast, the other afatinib-resistant cell lines, including
Calu3-ARH, H1781-ARS and H1781-ARH, which showed EMT or had acquired CSC-like features, showed maintained sensitivity to docetaxel, because ABCB1 was not upregulated in these acquired resistance cell lines.
| DISCUSSION
In this study, we established multiple cell lines that exhibited acquired resistance to the irreversible pan-HER inhibitor afatinib, . 28, 33 Consistent with that report, in this study also, conducted using HER2-altered NSCLC cells, the resistance mechanisms were affected by the manner of drug exposure. The resistance mechanism in the Calu3-ARS cells established by the stepwise escalation method appeared to be MET amplification, whereas that in the Calu3-ARH cells established by the high drug concentration method was considered to be possibly attributable to the acquisition of EMT features.
MET amplification is one of the major mechanisms underlying the acquisition of resistance to HER inhibitors in EGFR-mutant NSCLC. 28, 29, 33, 34 MET amplification has also been reported to contribute to trastuzumab resistance in HER2-positive breast cancer cells. 35 In this study, we identified MET amplification as one of the mechanisms underlying the acquisition of resistance of HER2-altered NSCLC to the pan-HER inhibitor afatinib. Importantly, we clarified that combined treatment with afatinib plus crizotinib, a MET inhibitor, was highly effective against HER2-altered NSCLC showing acquired resistance to afatinib, both in vitro and in vivo. These results suggest the importance of reassessment of tumor cells after the acquisition of resistance to afatinib; if such reassessment in clinical cases reveals MET amplification, then combined treatment with afatinib plus crizotinib should be considered.
In afatinib-resistant cell lines established from H2170 cells showing HER2 amplification, the copy number of HER2 decreased gradually during the course of exposure to afatinib. We previously reported loss of the EGFR-mutant allele and progressive decrease of the EGFR copy number in an EGFR-mutant NSCLC cell line during gefitinib exposure. 28 However, to the best of our knowledge, loss of HER2 amplification during afatinib treatment has never been reported before in in vitro examinations. However, loss of HER2 amplification has sometimes been reported after trastuzumab treatment in clinical HER2-positive breast or gastric cancer patients. [36] [37] [38] [39] Our finding seems to be consistent with these latter clinical reports.
Loss of HER2 amplification in the residual disease following neoadjuvant trastuzumab-based therapy has been reported to be associated with a poorer relapse-free survival when compared with maintained HER2 expression. 40 The biological basis of these genetic alterations has not been clarified yet, and might include tumor heterogeneity, genetic drift toward a more aggressive tumor phenotype, or selective pressure of adjuvant therapy. 38 Overexpression of ABCB1 has been reported to be strongly associated with EMT or the acquisition of CSC-like features; 41 therefore, the characteristics of the Calu3-ARH, H1781-ARS and H1781-ARH may differ somewhat from those of EGFR-TKI-resistant cells showing EMT or CSC-like features reported previously. 28, 33 Moreover, the precise molecular mechanisms underlying how EMT or CSC-like features lead to afatinib resistance remain unclear, and thorough investigation using resistance models established by us could yield clues to uncover these mechanisms.
In conclusion, we established 6 cell lines with acquired resistance to afatinib from 3 parental HER2-altered NSCLC cell lines. 
